Business Wire

21 Years of Airline Passenger Traffic Growth Wiped out in 2020: Cirium Report Reveals

29.12.2020 10:00:00 EET | Business Wire | Press release

Share

Global aviation data firm Cirium today released its new Airline Insights Review 2020 which reveals the shocking impact on aviation of worldwide travel restrictions to curb COVID-19.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201228005254/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cirium has today revealed a new 2020 review of aviation and air travel. The review includes key data insights from the past year and expert commentary from Cirium CEO, Jeremy Bowen, Henry Harteveldt, Dr. Mario Hardy and more. (Graphic: Business Wire)

The report shows that the pandemic and its consequences wiped out 21 years of global passenger traffic growth in a matter of months, reducing traffic this year to levels last seen in 1999. In comparison to last year, passenger traffic is estimated to be down 67% in 2020.

At the peak of the disruption in April, scheduled passenger flights dropped significantly to just 13,600 globally on April 25, compared to the year’s busiest day on January 3 when Cirium tracked over 95,000 scheduled passenger flights globally. This marks an extraordinary 86% reduction in flights.

From January to December airlines operated 49% fewer flights in 2020 compared to 2019 – down from 33.2 million flights to just 16.8 million (to December 20).

Domestic travel was down 40% this year, from 21.5 million flights in 2019, while international flights suffered an even more precipitous drop as they were 68% below the 11.7 million flights tracked the year before.

Jeremy Bowen, CEO of Cirium, said: “This severe setback shows the true extent of the challenge faced by the struggling aviation sector as it has sought to reset itself in the new post COVID-19 era.”

“Whereas this time last year we were celebrating the on-time performance of global carriers, this year is dramatically different. Most global airlines were largely on time in 2020; it’s just a shame that the traveling public, airlines and aviation firms worldwide didn’t benefit.

“The factors which usually cause delay, such as congested airspace, taxiways and late connecting passengers simply did not exist in 2020.”

The Cirium Airline Insights Review 2020 replaces Cirium’s annual On-Time Performance Review which for more than a decade has identified the world’s best performing airlines and airports for on-time flight operations.

NEW AIRLINE INSIGHTS REVIEW: FLIGHTS FLOWN DRAMATICALLY DOWN

Global passenger traffic figures reveal a plunge of over two thirds (67%) versus the previous year, with Asia-Pacific continuing to handle over a third of world passenger traffic.

The majority of the scheduled passenger flights flown this year have been domestic – totaling 13 million (77%) with a mere 3.8 million (23%) flying internationally, due to closed borders and limited business travel.

Cirium data analysis recorded Southwest Airlines operating the most flights globally (and in North America), with 854,800 flights in total. Meanwhile, China Southern Airlines (487,700 flights) topped the tables in the Asia-Pacific, Ryanair in Europe (205,000 flights), Azul in Latin America (134,000 flights) and Qatar Airways (82,400 flights) in the Middle East and Africa.

On the ground, Atlanta was the world’s busiest airport, handling over 245,000 arriving flights during 2020, while the world’s busiest air route in both directions was within South Korea, between Seoul and the island of Jeju with 70,700 flights operated.

Forward planning for airlines has dramatically contracted from six- to 12-months for flight scheduling to just six- to eight-weeks – forcing carriers to be nimbler and adapt with greater speed to the rapidly changing rules and travel restrictions around the world.

FLEETS IN STORAGE (BUT NOT THE A320)

As airlines have been forced to drastically reduce the number of aircraft still in service, those still flying are operating significantly fewer hours.

For example, narrowbody aircraft operated just six to seven hours a day in Q3 2020 compared to nine to 10 hours a day in the same period last year.

While up to 30% of the global passenger fleet remains in storage there are signs of recovery on the horizon, with only 10% of short-haul Airbus A320neo aircraft currently in storage showing narrowbody aircraft leading the recovery and domestic and short-haul travel returning first.

With domestic and short-haul services ruling the day, the world’s most used aircraft type was the Airbus A320 with Cirium tracking 5.49 million flights throughout 2020.

SEVEN TRENDS IDENTIFIED BY CIRIUM

“Airlines will have a way before returning to 2019 levels particularly as international travel is significantly down and showing only slow signs of recovery, mainly China and Southeast Asia,” Jeremy Bowen added.

“But Cirium is confident aviation will weather this difficult and terrible year and emerge in better shape – with younger more fuel-efficient aircraft and right-sized fleets – to gradually navigate their way to recovery in the years ahead.”

The seven key trends outlined by The Cirium Airline Insights Review 2020 for next year include:

  1. The consolidation of airlines, particularly in Asia-Pacific where more domestic competitors will merge or be acquired.
  2. New-generation aircraft like the A320neo and the return of the 737 Max, will provide reduced operating costs.
  3. Surplus aircraft will be retired and the Boeing 747 and the Airbus A380 are projected to support the rising demand in the denser leisure markets.
  4. In Q4 we saw a 78% plunge in bookings compared to the same period last year – this will naturally change the way the industry forecasts demand, we are seeing on-line search and sentiment becoming the primary indicators to calculate demand.
  5. Airlines will need to deploy more dynamic scheduling with the increased volatility of flight scheduling, as the booking window has fallen from six- to 12-months to just six- to eight-weeks.
  6. The implementation of AI technology will accelerate to automate the traveler experience and real-time proactive information will become more critical.
  7. Aircraft leasing will push past 50% becoming the major manner in which aircraft are financed.

To read the full Cirium Airline Insights Review 2020 – click here.

Bowen thanked the OTP board members comprised of Henry Harteveldt at Atmosphere Research group and Dr. Mario Hardy at Pacific Asia Travel Association (PATA) for their insights and contributions to the Airline Insight Review 2020.

For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter.

About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries please contact,
In the UK: Paul Charles / Michael Johnson / Balint Brunner at The PC Agency via cirium@pc.agency or +44 207 768 0001
In the Americas: Mike Arnot, at Juliett Alpha via cirium@juliettalpha.com
In Asia-Pacific: Tracy Cheung, at Cirium via tracy.cheung@cirium.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye